Proton Magnetic Resonance in Tincalconite

From the 1proton magnetic resonance spectra of tincalconite r ecorded between -1530C and + aooc OH - groups and water molecules were estabHshed. By dehydration at aaoc over P 2 0 5 in vacuum tincalconite loses three water molecules per formula unit with an amoophous rest. The proton resonance line-shape of this dehydration product corresponds to the OH-groups spectrum. The comparison of the experimental curve at low temperature with theoretical ones for two different ratios OH:H20 suggests Na2[B 405(0H)4] · 3H20 as the correct formula for tincalconite. The nature of the motion of the water molecules is discussed

Strategies for the purification of hydroxytyrosol-rich extracts obtained from exhausted olive pomace

ABSTRACT: Exhausted olive pomace (EOP) is a residual biomass from which hydroxytyrosol can be recovered. This compound has applications in the food/pharma sectors, but its extraction yields complex extracts that require further purification for some applications. This work explores purification strategies based on membrane technology, liquid–liquid extraction (LLE), and solid-phase extraction with adsorbents and resins. The hydroxytyrosol content, phenolic profile, antioxidant activity, and inhibition of α-glucosidase and α-amylase were monitored. Hydroxytyrosol stood out in all purified extracts. The best hydroxytyrosol recovery (88.8%) was achieved using LLE with ethyl acetate as the extractant, while the purest extracts in phenolic compounds, including hydroxytyrosol, were obtained using the latter solvent and C18 (529 mg/g), DSC-8 (873 mg/g), and Purosorb PAD910 (523 mg/g). Conversely, mannitol and glucose, at high concentrations in the extract, were selectively retained in the aqueous phases. The developed strategies are discussed regarding their suitability to provide hydroxytyrosol-concentrated extracts, up to 291 mg/g, with antioxidant and antidiabetic functionalities.info:eu-repo/semantics/publishedVersio

Desenvolvimento de processos de pré-tratamento da biomassa para a separação eficiente das correntes de lenhina e de açúcares

CIES2020 - XVII Congresso Ibérico e XIII Congresso Ibero-americano de Energia SolarRESUMO: O fracionamento da biomassa é um dos principais pontos críticos no desenvolvimento das biorrefinarias. Neste trabalho, são apresentadas três estratégias inovadoras com vista à separação seletiva das frações de celulose, hemicelulose e lenhina, utilizando compostos orgânicos, geralmente em solução aquosa: i) utilização de líquidos iónicos (ILs) em particular [emim][OAc] e [emim][HSO4]); ii) processos organosolv baseados na utilização de misturas etanol:água (50:50); e iii) um processo não aquoso baseado em imidazole. Os processos com ILs permitiram um fracionamento diferencial e, em geral, uma redução da cristalinidade da celulose. Os processos organosolv permitiram modular a distribuição de produtos derivados da hemicelulose e da lenhina entre as fases sólida e líquida. A utilização de imidazole, permitiu a separação das duas frações de polissacáridos e contribuiu para despolimerização da lenhina.ABSTRACT: The biomass fractionation is one of the main critical points in the technological development of biorefineries. In this work, three innovative fractionation strategies aiming the selective separation of the cellulose, hemicellulose and lignin fractions, using organic compounds, generally in aqueous solution, are presented and discussed: i) use of ionic liquids (ILs), in particular [emim][OAc ] and [emim][HSO4]); ii) organosolv process based on ethanol:water mixture (50:50); and iii) a non-aqueous process based on imidazole. The processes with ILs allowed a differential fractionation and, in general a decrease of cellulose crystallinity. The organosolv process enabled the modulation of the distribution of hemicellulose and lignin-derived products between the solid phase and the liquid phase. The use of imidazole, allowed the separation of the two polysaccharide fractions and contributed to lignin depolymerization, producing phenolic compounds whose molecular weight is a function of severity.info:eu-repo/semantics/publishedVersio

Bringing onco‐innovation to Europe’s healthcare systems. The potential of biomarker testing, real world evidence, tumour agnostic therapies to empower personalised medicine

Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre‐eminently in many cancers, but also in an ever‐wider range of conditions— notably BRCA1/2 testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by country‐related heterogeneity, data deficiencies, and lack of policy alignment on standards, approval—and the role of real‐world evidence in the process—and reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europe’s industrial competitiveness and innovation require an appropriate policy framework—starting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients

Bringing onco-innovation to Europe’s healthcare systems: the potential of biomarker testing, real world evidence, tumour agnostic therapies to empower personalised medicine

International audienceRapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre-eminently in many cancers, but also in an ever-wider range of conditions—notably BRCA1/2 testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by country-related heterogeneity, data deficiencies, and lack of policy alignment on standards, approval—and the role of real-world evidence in the process—and reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europe’s industrial competitiveness and innovation require an appropriate policy framework—starting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients

Wild species of vaccinium composition, nutritional value and utilization

There are still, in many parts of the globe, some edible fruit collects from the wild for human feeding and other uses. These fruits are utilised either in their raw nature or after some form of processing. One of these wild fruits are Vaccinium species such as Vaccinium myrtoides (Blume) Miq., Vaccinium cylindraceum, Vaccinium padifolium, Vaccinium corymbosum, Vaccinium myrtillus and others from the plant family Ericaceae. The term wild infers non-cultivated plants found in plantation felids or the forest. The species Vaccinium myrtoides and the others are small trees (shrubs) that are well known in Southeast Asian countries such as Philippines, Indonesia and other neighbouring islands. The plants classified as wild growing shrubs. However, the locals have made it be fully utilized in some areas as the wood that are used in grafting utensils and cutleries, or as fuel and fruits. The small-sized berry-like fruits with an average diameter of about 4–5 mm turn black when ripe. They have a delicious flavour that makes it edible and used in the making of other delicacies such as tart and pies to add flavour and as preservatives as well. A few published researches were done on Vaccinium myrtoides showing that it is still used in folkloric medicine. Leaves and fruits extracts showed strong antioxidant activity when tested in-vitro using DPPH (2, 2-diphenyl-1-picrylhydrazyl) free radical scavenging activity as part of a preliminary phytochemical screening for V. myrtoides. The study revealed that the antioxidant activity is due to the presence of flavonoids and other phenolic compounds in the plant leaves and fruit extracts

Bringing onco‐innovation to Europe’s healthcare systems: The potential of biomarker testing, real world evidence, tumour agnostic therapies to empower personalised medicine

Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre‐eminently in many cancers, but also in an ever‐wider range of conditions— notably BRCA1/2 testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by country‐related heterogeneity, data deficiencies, and lack of policy alignment on standards, approval—and the role of real‐world evidence in the process—and reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europe’s industrial competitiveness and innovation require an appropriate policy framework—starting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients

Urban space and the social control of incivilities: perceptions of space influencing the regulationof anti-social behaviour

Contemporary cities are increasingly governed through space. In this article,we examine how urban space and perceptions thereof can influence the social control inthe area of incivilities. To this end, we first inspect the existing literature, in particularthe socio-spatial studies that emphasise the importance of culture and values in theinteraction with social control. Partly drawing on examples from our previous studies,we suggest that people’s perceptions of urban space (influenced by cultural symbols,social and media representations, aesthetics and other values) affect their perceptions ofincivilities, while the latter often determine or at least importantly contribute to theshaping of the social control of incivilities. We further highlight the role of gentrifica-tion as a medium and a tool of social control. The paper concludes by discussingimplications of this for the possible future, more integrated and interdisciplinaryresearch on the social control of incivilities in the city

Strategic programming of innovation and competitiveness of Polish economy development

W artykule podjęto próbę analizy kierunków rozwoju innowacyjności polskiej gospodarki w świetle wybranych rządowych programów strategicznych. Przedmiot analizy stanowiły głównie programowe działania administracji rządowej, ukierunkowane na adaptację polskiej gospodarki do zmieniających się warunków ekonomicznych, politycznych i społecznych, mające na celu podnoszenie poziomu innowacyjności i konkurencyjności. Analizie poddano również strategie rozwojowe sfery naukowo-badawczej w kontekście jej relacji z gospodarką. Zagadnienia te stanowiły genezę artykułu, głównie ze względu na zainteresowania autorki, dotyczące procesów ukierunkowywania prac rozwojowych i wdrożeniowych podejmowanych przez jednostki naukowo-badawcze w priorytetowych dla polskiej gospodarki oraz preferowanych zgodnie z unijnymi i ogólnoświatowymi trendami, obszarach transferu wiedzy i nowoczesnych technologii do gospodarki [1].The article presents the results of analysis of directions of innovation development of the Polish economy in the light of selected governmental strategic programmes. The subject of the analysis constitutes mainly government administration activities oriented to the adaptation of the Polish economy to changing economic, political and social conditions, which aim at the increase of the innovation and competitiveness level. The development strategies concerning the scientific-research area and its relations with the economy are also analysed

Was der Mythos der modernen Geographie nach Kiel ausschließt

No abstract available